TY - JOUR
T1 - SHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium
AU - O'Donnell, Jonathan E.M.
AU - Hastings, Lucy A.
AU - Briody, Julie N.
AU - Chan, Christine L.
AU - Colombo, Carla
AU - Douglas, Tonia A.
AU - Freedman, Steven D.
AU - Gonska, Tanja
AU - Greenfield, Jerry R.
AU - Leung, Daniel H.
AU - Lim, Adeline Y.L.
AU - Moran, Antoinette
AU - Prentice, Bernadette J.
AU - Putman, Melissa S.
AU - Trotter, Michael
AU - Tullis, Elizabeth
AU - Westall, Glen P.
AU - Verge, Charles F.
AU - Wainwright, Claire E.
AU - Ooi, Chee Y.
AU - Engelhardt, John F.
AU - Katz, Tamarah
AU - King, Susannah
AU - Lewindon, Peter J.
AU - Matson, Angela G.
AU - McDonald, Catherine M.
AU - Moheet, Amir
AU - Narkewicz, Michael R.
AU - Oliver, Mark
AU - Ramm, Grant A.
AU - Sellers, Zachary M.
AU - Wilschanski, Michael
N1 - Publisher Copyright:
© 2024 The Authors. Pediatric Pulmonology published by Wiley Periodicals LLC.
PY - 2024/6
Y1 - 2024/6
N2 - Background: Cystic fibrosis (CF) is a life-shortening multisystem genetic disease. Although progressive pulmonary disease is the predominant cause of morbidity and mortality, improvements in treatment for CF-related lung disease, with associated increase in longevity, have increased the prevalence of extrapulmonary manifestations1. Methods: To discuss these issues, a multidisciplinary meeting of international leaders and experts in the field was convened in November 2021 at the Shaping Initiatives and Future Trends Symposium with the goal of highlighting shifting management paradigms in CF. The main topics covered were: (1) nutrition and obesity, (2) exocrine pancreas, (3) CF-related diabetes, (4) CF liver disease, (5) CF-related bone disease, and (6) post-lung transplant care. This document summarizes the proceedings, highlighting the key priorities and important research questions that were discussed. Results: Improved life expectancy, the advent of cystic fibrosis transmembrane conductance regulator modulators, and the increasing appreciation of the heterogeneity or spectrum of disease are leading to a shift in management for patients with cystic fibrosis. Care should be individualized to ensure that increased longevity is accompanied by improved extra-pulmonary care and reduced morbidity.
AB - Background: Cystic fibrosis (CF) is a life-shortening multisystem genetic disease. Although progressive pulmonary disease is the predominant cause of morbidity and mortality, improvements in treatment for CF-related lung disease, with associated increase in longevity, have increased the prevalence of extrapulmonary manifestations1. Methods: To discuss these issues, a multidisciplinary meeting of international leaders and experts in the field was convened in November 2021 at the Shaping Initiatives and Future Trends Symposium with the goal of highlighting shifting management paradigms in CF. The main topics covered were: (1) nutrition and obesity, (2) exocrine pancreas, (3) CF-related diabetes, (4) CF liver disease, (5) CF-related bone disease, and (6) post-lung transplant care. This document summarizes the proceedings, highlighting the key priorities and important research questions that were discussed. Results: Improved life expectancy, the advent of cystic fibrosis transmembrane conductance regulator modulators, and the increasing appreciation of the heterogeneity or spectrum of disease are leading to a shift in management for patients with cystic fibrosis. Care should be individualized to ensure that increased longevity is accompanied by improved extra-pulmonary care and reduced morbidity.
KW - cystic fibrosis
KW - cystic fibrosis bone disease
KW - cystic fibrosis related diabetes
KW - cystic fibrosis related liver disease
KW - exocrine pancreatic disease
KW - extra-pulmonary complications cystic fibrosis
KW - lung transplant
KW - nutrition
UR - http://www.scopus.com/inward/record.url?scp=85190523706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85190523706&partnerID=8YFLogxK
U2 - 10.1002/ppul.26970
DO - 10.1002/ppul.26970
M3 - Article
AN - SCOPUS:85190523706
SN - 8755-6863
VL - 59
SP - 1661
EP - 1676
JO - Pediatric pulmonology
JF - Pediatric pulmonology
IS - 6
ER -